阿卡波糖片控制2型糖尿病患者血糖的临床观察

Clinical observation of acarbose glycemic control in patients with type 2 diabetes

目的:观察单独使用阿卡波糖片对初治糖化血红蛋白(HbA1c)<8.5%的2型糖尿病(T2DM)患者血糖水平的控制效果。方法:对单独使用阿卡波糖片或二甲双胍肠溶胶囊的T2DM患者治疗前及治疗后6个月的血糖、HbA1c、血脂、体质量指数(BMI)的变化进行比较。结果:两种药物单独使用均可使T2DM患者血糖、HbA1c下降,差异均有统计学意义(P<0.05)。两药之间比较差异无统计学意义(P>0.05)。结论:阿卡波糖片能有效控制T2DM患者血糖及HbA1c水平。

Objective:To observe the blood glucose level control of the separate use of acarbose in the treatment of primary glycosylated hemoglobin(Hb A1c)<8.5% in patients with type 2 diabetes mellitus(T2DM).Methods:We compared the changes of blood lipid, blood glucose, Hb A1 c, body mass index(BMI) of T2 DM patients who use the acarbose or metformin enteric coated capsules separately before and after the treatment 6 months.Results:The two kinds of drug used alone can make the blood glucose and Hb A1 c decreased in T2 DM patients,and there were significant differences(P<O.05).There was no significant difference between the two drugs(P>O.05).Conclusion:The acarbose can effectively control blood glucose and Hb A1 c levels in patients with T2 DM.